{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:33:56Z","timestamp":1788366836756,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40291-023-00648-z","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T08:01:15Z","timestamp":1680681675000},"page":"425-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tabelecleucel: First Approval"],"prefix":"10.1007","volume":"27","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"5","key":"648_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/CCO.0000000000000885","volume":"34","author":"D Dierickx","year":"2022","unstructured":"Dierickx D, Pociupany M, Natkunam Y. Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment. Curr Opin Oncol. 2022;34(5):413\u201321.","journal-title":"Curr Opin Oncol"},{"key":"648_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100807","volume":"49","author":"A Ohmoto","year":"2021","unstructured":"Ohmoto A, Fuji S. Clinical features and treatment strategies for post-transplant and iatrogenic immunodeficiency-associated lymphoproliferative disorders. Blood Rev. 2021;49: 100807.","journal-title":"Blood Rev"},{"key":"648_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.838817","volume":"12","author":"K Lv","year":"2022","unstructured":"Lv K, Yin T, Yu M, et al. Treatment advances in EBV related lymphoproliferative diseases. Front Oncol. 2022;12: 838817.","journal-title":"Front Oncol"},{"key":"648_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2022.101260","volume":"56","author":"SS Soldan","year":"2022","unstructured":"Soldan SS, Messick TE, Lieberman PM. Therapeutic approaches to Epstein-Barr virus cancers. Curr Opin Virol. 2022;56: 101260.","journal-title":"Curr Opin Virol"},{"key":"648_CR5","unstructured":"European Medicines Agency. Tabelecleucel: EPAR\u2014public assessment report. 2022. https:\/\/www.ema.europa.eu\/. Accessed 22 Jan 2023."},{"issue":"Suppl 1","key":"648_CR6","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1182\/blood-2021-147307","volume":"138","author":"V Dharnidharka","year":"2021","unstructured":"Dharnidharka V, Thirumalai D, Jaeger U, et al. Clinical outcomes of solid organ transplant patients with Epstein-Barr virus-driven (EBV+) post-transplant lymphoproliferative disorder (PTLD) who fail rituximab plus chemotherapy: a multinational, retrospective chart review study [abstract no. 2528]. Blood. 2021;138(Suppl 1):2528.","journal-title":"Blood"},{"issue":"Suppl 1","key":"648_CR7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/blood-2021-147296","volume":"138","author":"J Sanz","year":"2021","unstructured":"Sanz J, Storek J, Soci\u00e9 G, et al. Clinical outcomes of patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following hematopoietic stem cell transplantation who fail rituximab: a multinational, retrospective chart review study [abstract no. 1454]. Blood. 2021;138(Suppl 1):1454.","journal-title":"Blood"},{"key":"648_CR8","unstructured":"European Medicines Agency. Tabelecleucel: EU prescribing information 2022. https:\/\/www.ema.europa.eu\/. Accessed 23 Jan 2023."},{"key":"648_CR9","unstructured":"Atara Biotherapeutics Inc. Atara Biotherapeutics\u2019 Ebvallo\u2122 (tabelecleucel) receives European Commission Approval as first ever therapy for adults and children with EBV+ PTLD [media release]. 19 Dec 2022. https:\/\/investors.atarabio.com\/."},{"key":"648_CR10","unstructured":"Atara Biotherapeutics Inc. Atara Biotherapeutics to receive additional near-term milestone payment under updated tabelecleucel (tab-cel\u00ae) commercialization agreement with Pierre Fabre [media release]. 28 Sep 2022. https:\/\/www.atarabio.com\/."},{"key":"648_CR11","unstructured":"Atara Biotherapeutics inc. Atara Biotherapeutics and Pierre Fabre enter strategic collaboration to commercialize tabelecleucel (tab-cel\u00ae) [media release]. 4 Nov 2021. https:\/\/www.atarabio.com\/."},{"key":"648_CR12","unstructured":"Atara Biotherapeutics Inc. Form 10-K. 2022. https:\/\/investors.atarabio.com\/. Accessed 20 Jan 2023."},{"key":"648_CR13","unstructured":"Atara Biotherapeutics Inc. Atara Biotherapeutics and QIMR Berghofer Medical Research Institute announce exclusive license and research agreements [media release]. 21 Oct 2015. https:\/\/www.atarabio.com\/."},{"key":"648_CR14","unstructured":"Atara Biotherapeutics Inc. Atara Biotherapeutics announces immunotherapy alliance with Memorial Sloan Kettering Cancer Center [media release]. 23 Sep 2014. https:\/\/www.atarabio.com\/."},{"key":"648_CR15","unstructured":"Atara Biotherapeutics Inc. Atara Biotherapeutics exercises exclusive license to T-cell technology from Memorial Sloan Kettering Cancer Center [media release]. 15 Jun 2015. https:\/\/www.atarabio.com\/."},{"issue":"2","key":"648_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1172\/JCI121127","volume":"130","author":"S Prockop","year":"2020","unstructured":"Prockop S, Doubrovina E, Suser S, et al. Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation. J Clin Invest. 2020;130(2):733\u201347.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"648_CR17","doi-asserted-by":"publisher","first-page":"10374","DOI":"10.1182\/blood-2022-157766","volume":"140","author":"KM Mahadeo","year":"2022","unstructured":"Mahadeo KM, Baiocchi R, Beitinjaneh A, et al. New and updated results from a multicenter, open-label, global phase 3 study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (ALLELE) [abstract no. 4658]. Blood. 2022;140(Suppl 1):10374\u20136.","journal-title":"Blood"},{"key":"648_CR18","doi-asserted-by":"crossref","unstructured":"Nikiforow S, Baiocchi R, Nasta S, et al. Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease [abstract no. 1658]. In: 62nd Annual Meeting and Exposition of the American Society of Hematology. 2020.","DOI":"10.1016\/j.annonc.2020.08.1171"},{"issue":"3 Suppl","key":"648_CR19","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.bbmt.2019.12.228","volume":"26","author":"SE Prockop","year":"2020","unstructured":"Prockop SE, Reshef R, Tsai DE, et al. Long-term outcomes of patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ transplant or allogeneic hematopoietic cell transplant treated with tabelecleucel in a multicenter expanded access program study [abstract no. 81]. Biol Blood Marrow Transplant. 2020;26(3 Suppl):S61\u20132.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"Suppl 1","key":"648_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1182\/blood-2021-147226","volume":"138","author":"S Prockop","year":"2021","unstructured":"Prockop S, Gamelin L, Dinavahi R, et al. Overall survival by best overall response with tabelecleucel in patients with Epstein-Barr virus-driven post-transplant lymphoproliferative disease following solid organ or allogeneic hematopoietic cell transplant [abstract no. 887]. Blood. 2021;138(Suppl 1):887.","journal-title":"Blood"},{"issue":"16 Suppl","key":"648_CR21","doi-asserted-by":"publisher","first-page":"7530","DOI":"10.1200\/JCO.2022.40.16_suppl.7530","volume":"40","author":"S Choquet","year":"2022","unstructured":"Choquet S, Chaganti S, Uttenthal B, et al. Demographics and treatment outcomes in patients with EBV+ PTLD treated with off-the-shelf EBV-specific CTL under an ongoing expanded access program in Europe: first analyses [abstract no. 7530]. J Clin Oncol. 2022;40(16 Suppl):7530.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"648_CR22","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.1182\/blood-2022-157765","volume":"140","author":"L Jim\u00e9nez-Kurlander","year":"2022","unstructured":"Jim\u00e9nez-Kurlander L, Behr G, Bunin N, et al. Updated efficacy and safety of tabelecleucel in patients with Epstein-Barr virus-positive (EBV+) leiomyosarcomas (LMS) [abstract no. 3349]. Blood. 2022;140(Suppl 1):7524\u20136.","journal-title":"Blood"},{"key":"648_CR23","doi-asserted-by":"crossref","unstructured":"Prockop S, Dinavahi R, Navarro W, et al. A multicenter, multicohort, open-label, single-arm per cohort, phase II study to assess the efficacy and safety of tabelecleucel in patients with EBV-associated diseases using an adaptive two-stage study design [abstract no. 2551]. In: 62nd Annual Meeting and Exposition of the American Society of Hematology. 2020.","DOI":"10.1182\/blood-2020-136075"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-023-00648-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T03:32:05Z","timestamp":1682998325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-023-00648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s40291-023-00648-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"21 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}